Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509860 | 0.97 | TLR2 (0.40) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL1510027 | 0.97 | TLR2 (0.40) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL11922646 | 0.95 | HPGD (0.38) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL1509877 | 0.94 | KMT2A (0.38) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL1509890 | 0.94 | KMT2A (0.38) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL1676784 | 0.91 | TLR2 (0.40) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL12806518 | 0.91 | TLR2 (0.40) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL20467703 | 0.91 | TLR2 (0.40) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL15579833 | 0.90 | TLR2 (0.40) | HPGDHTTSMN1; SMN2GLP1RTLR2 | |
| SCHEMBL11922697 | 0.89 | KMT2A (0.36) | HPGDHTTSMN1; SMN2GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859493-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| EP-2292653-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2014-05-21 | — | — | EP | disclosed |
| EP-1846447-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-08-21 | — | — | EP | disclosed |
| US-20120208749-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-08-16 | — | — | US | disclosed |
| EP-2292653-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| EP-1846447-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082205-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227796-A1 | Insulin Derivatives | IAPP, INSR, GCG | HPGD 1717/4885HTT 3257/4885SMN1; SMN2 4544/4885 |
| US-20120208749-A1 | Insulin derivatives | IAPP, INSR, GCG | HPGD 2207/4885HTT 3424/4885SMN1; SMN2 4611/4885 |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | HPGD 768/4885HTT 3095/4885SMN1; SMN2 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.